Johnson & Johnson (JNJ) Long-Term Debt Issuances (2009 - 2025)

Johnson & Johnson's (JNJ) quarterly Long-Term Debt Issuances came in at $9.1 billion in Q1 2025, up 456800.0% year-on-year from N/an in Q1 2024, and up 913700.0% quarter-over-quarter from $1.0 million in Q3 2024.

Johnson & Johnson (JNJ) Long-Term Debt Issuances (2009 - 2025) Analysis & Trends

Johnson & Johnson has disclosed Long-Term Debt Issuances across 15 years of filings, most recently posting $9.1 billion for Q1 2025.

  • Long-Term Debt Issuances for Q1 2025 came in at $9.1 billion, up 456800.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.1 billion (up 37.21% YoY), and the FY2025 annual result was $9.1 billion, up 37.21% from the prior year.
  • Long-Term Debt Issuances came in at $9.1 billion for Q1 2025 at Johnson & Johnson, up from $1.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $9.1 billion in Q1 2025 to a low of -$7.7 billion in Q4 2023.
  • The 4-year median for Long-Term Debt Issuances is $2.0 million (2021), against an average of $1.8 billion.
  • Across the five-year window, Long-Term Debt Issuances tumbled 99.97% in 2024 and soared 456800.0% in 2025, its largest moves.
  • Johnson & Johnson's Long-Term Debt Issuances stood at $2.0 million in 2021, then tumbled by 383800.0% to -$7.7 billion in 2023, then soared by 100.01% to $1.0 million in 2024, then surged by 913700.0% to $9.1 billion in 2025.
  • The last three Long-Term Debt Issuances figures came in at $9.1 billion (Q1 2025), $1.0 million (Q3 2024), and $6.7 billion (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 7.99 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 3.96 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn -
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 30, 2025 9.14 Bn
Mar 30, 2025 9.14 Bn
Sep 29, 2024 1.00 Mn
Sep 29, 2024 1.00 Mn
Jun 30, 2024 6.66 Bn
Jun 30, 2024 6.66 Bn
Mar 31, 2024 2.00 Mn
Mar 31, 2024 2.00 Mn
Oct 1, 2023 -7.67 Bn
Oct 1, 2023 -7.67 Bn
Apr 2, 2023 7.67 Bn
Apr 2, 2023 7.67 Bn
Jan 1, 2023 -1.00 Mn
Jan 1, 2023 -1.00 Mn
Oct 3, 2021 2.00 Mn
Oct 3, 2021 2.00 Mn
Apr 4, 2021 1.00 Mn
Apr 4, 2021 1.00 Mn
Sep 27, 2020 7.43 Bn
Sep 27, 2020 7.43 Bn